Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients

Diabetes and Vascular Disease Research

Volumn 6, Issue 2, 2009, Pages 87-93

  Vanasse, Alain ^a,b   Carpentier, André C ^a   Courteau, Josiane ^b   Asghari, Shabnam ^b  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; EVALUATION; FEMALE; HOSPITAL ADMISSION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; RETROSPECTIVE STUDY; STROKE;

EID: 68349084416     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.1177/1479164109336047     Document Type: Article

References (18)

1. Santé Canada, Therapeutic Products Directorate (2001) Canadian Adverse Drug Reaction: Newsletter 11(3). Available at: http://www.hc-sc.gc.ca/ dhp-mps/medeff/bulletin/carn-bcei-v11n3-e.html#rosiglitazone
2. Delea, TE, Edelsberg, JS, Hagiwara, M, Oster, G, Phillips, LS (2003) Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes. Diabetes Care 26: 2983-2989
3. Erdmann, E, Charbonnel, B, Wilcox, RG, et al., on behalf of the PROactive investigators (2007) Pioglitazone use and heart failure in patients with type-2 diabetes and pre-existing cardiovascular disease. Diabetes Care 30: 2773-2778
4. Nissen, SE, Wolski, K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471 (Pubitemid 46919772)
5. Shuster, JJ, Jones, LS, Salmon, DA (2007) Fixed vs random effects meta-analysis in rare event studies: The rosiglitazone link with myocardial infarction and cardiac death. Stat Med 26: 4375-4385
6. McAfee, AT, Koro, C, Landon, J, Ziyadeh, N, Walker, AM (2007) Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 16: 711-725 (Pubitemid 47180361)
7. Diamond, GA, Bax, L, Kaul, S (2007) Uncertain effects of rosiglitazone on the risk of myocardial infarction and cardiovascular death. Ann Intern Med 147: 578-582 (Pubitemid 351664507)
8. Gerrits, CM, Bhattacharya, M, Manthena, S, Baran, R, Perez, A, Kupfer, S (2007) A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 16: 1065-1071 (Pubitemid 350020057)
9. Singh, S, Loke, YK, Furberg, CD (2007) Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA 298: 1189-1195 (Pubitemid 47403105)
10. Lipscombe, LL, Gomes, T, Lévesque, LE, Hux, JE, Juurlink, D.N., Alter, D.A. (2007) Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298: 2634-2643
11. Ministère de la Santé et des Services Sociaux du Québec (MSSS). Cadre normatif Med-Écho - Mise à jour 2007. Available at:- http://msssa4.msss.gouv.qc.ca/fr/document/publication. nsf/961885cb24e4e9fd85256b1e00641a29/ee0d0c3d13c5326e8525715d0053f644? OpenDocument (accessed April 2008).
12. Régie de l'Assurance Maladie du Québec (RAMQ). Overview of the databases owned and administered by the RAMQ. Available at: http://www.ramq.gouv.qc.ca/en/statistiques/banques/vuedensemble.shtml (accessed April 2008).
13. Blanchard, JF, Ludwig, S, Wajda, A, Dean, H, Anderson, K, Kendall, O, et al. (1996) Incidence and Prevalence of Diabetes in Manitoba, Diabetes Care 19(8): 807-811 (Pubitemid 26286983)
14. Hux, JE, Ivis, F, Flintoft, V, Bica, A (2002) Diabetes in Ontario: Determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25: 512-516 (Pubitemid 41103345)
15. Essebag, V, Platt, RW, Abrahamowicz, M, Pilote, L (2005) Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 5:5 doi:10.1186/1471-2288-5-5. (Pubitemid 40317980)
16. Jeremias, A, Gibson, CM (2005) Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med 142: 786-791 (Pubitemid 40593781)
17. ClinicalTrials.gov, a service of the US National Institute of Health. List of clinical trials involving rosiglitazone. Available at: http://clinicaltrials.gov/ct2/results?term=rosiglitazone%2C+atherosclerosis (accessed April 2008).
18. Vanasse, A, Asghari, S, Courteau, J, Carpentier, AC Pattern of diabetes therapeutic prescription in rural and urban areas in Quebec. Canadian Diabetes Association: Professional Conference and Annual Meeting. Poster presentation. October 15-18 2008.